tert-butyl N-(1-amino-2-hydroxy-1-oxohexan-3-yl)carbamate | 875628-53-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl N-(1-amino-2-hydroxy-1-oxohexan-3-yl)carbamate
• CAS: 875628-53-8
• 化学式: C₁₁H₂₂N₂O₄
• 分子量: 246.307
• InChiKey: MSYIXHBFQQCTIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl N-(1-amino-2-hydroxy-1-oxohexan-3-yl)carbamate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 以100%的产率得到3-amino-2-hydroxyhexanoic acid amide hydrochloride
  参考文献：
  名称：

  丙型肝炎病毒NS3蛋白酶的有效7-羟基-1,2,3,4-四氢异喹啉-3-羧酸基大环抑制剂。

  摘要：

  丙型肝炎病毒（HCV）的NS3蛋白酶已成为下一代HCV治疗的最有特色的靶标之一。四肽1和五肽2是具有中等效力的α-酮酰胺型HCV丝氨酸蛋白酶抑制剂。我们设想了1,2,3,4-四氢异喹啉-3-羧酰胺（Tic）部分可以被环化为P3封端基团。所得的大环化合物可通过其与Ala156甲基的额外接触来增强结合。大环化还可以提供肽含量较低的HCV抑制剂。从二肽5开始合成，其是通过两个氨基酸衍生物的偶联而获得的。将N-末端封端为庚-6-烯酰胺，得到6。双键的氢硼化得到醇7，大环8的前体。在Mitsunobu条件下实现了大环化（PPh（3），ADDP）。然后，将大环酸9与适当的右侧片段12、14或16结合，该片段由共同的中间体11制备。最后，α-羟酰胺的氧化提供了目标分子α-酮酰胺17、18和21。然后将末端酯加工成羧酸19和20，以及酰胺20和23。在HCV NS3蛋白酶连续测定中测试了抑制剂17-23。

  DOI：

  10.1021/jm050520a
• 作为产物：
  描述：

  2-hydroxy-3-nitrohexanoic acid 在 N-甲基吗啉 、 palladium on activated charcoal sodium hydroxide 、 ammonium chloride 、 氢气 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 3-羟基-1,2,3-苯并三嗪-4(3H)-酮 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， -20.0~20.0 ℃ 、406.79 kPa 条件下， 反应 21.17h， 生成 tert-butyl N-(1-amino-2-hydroxy-1-oxohexan-3-yl)carbamate
  参考文献：
  名称：

  丙型肝炎病毒NS3蛋白酶的有效7-羟基-1,2,3,4-四氢异喹啉-3-羧酸基大环抑制剂。

  摘要：

  丙型肝炎病毒（HCV）的NS3蛋白酶已成为下一代HCV治疗的最有特色的靶标之一。四肽1和五肽2是具有中等效力的α-酮酰胺型HCV丝氨酸蛋白酶抑制剂。我们设想了1,2,3,4-四氢异喹啉-3-羧酰胺（Tic）部分可以被环化为P3封端基团。所得的大环化合物可通过其与Ala156甲基的额外接触来增强结合。大环化还可以提供肽含量较低的HCV抑制剂。从二肽5开始合成，其是通过两个氨基酸衍生物的偶联而获得的。将N-末端封端为庚-6-烯酰胺，得到6。双键的氢硼化得到醇7，大环8的前体。在Mitsunobu条件下实现了大环化（PPh（3），ADDP）。然后，将大环酸9与适当的右侧片段12、14或16结合，该片段由共同的中间体11制备。最后，α-羟酰胺的氧化提供了目标分子α-酮酰胺17、18和21。然后将末端酯加工成羧酸19和20，以及酰胺20和23。在HCV NS3蛋白酶连续测定中测试了抑制剂17-23。

  DOI：

  10.1021/jm050520a

文献信息

• Novel Potent Hepatitis C Virus NS3 Serine Protease Inhibitors Derived from Proline-Based Macrocycles
  作者：Kevin X. Chen、F. George Njoroge、Ashok Arasappan、Srikanth Venkatraman、Bancha Vibulbhan、Weiying Yang、Tejal N. Parekh、John Pichardo、Andrew Prongay、Kuo-Chi Cheng、Nancy Butkiewicz、Nanhua Yao、Vincent Madison、Viyyoor Girijavallabhan

  DOI：10.1021/jm050820s

  日期：2006.2.1

  The hepatitis C virus (HCV) NS3 protease is essential for viral replication. It has been a target of choice for intensive drug discovery research. On the basis of an active pentapeptide inhibitor, 1, we envisioned that macrocyclization from the P2 proline to P3 capping could enhance binding to the backbone Ala156 residue and the S4 pocket. Thus, a number of P2 proline-based macrocyclic alpha-ketoamide inhibitors were prepared and investigated in an HCV NS3 serine protease continuous assay (K-i*). The biological activity varied substantially depending on factors such as the ring size, number of amino acid residues, number of methyl substituents, type of heteroatom in the linker, P3 residue, and configuration at the proline C-4 center. The pentapeptide inhibitors were very potent, with the C-terminal acids and amides being the most active ones (24, K-i* = 8 nM). The tetrapeptides and tripeptides were less potent. Sixteen- and seventeen-membered macrocyclic compounds were equally potent, while fifteen-membered analogues were slightly less active. gem-Dimethyl substituents at the linker improved the potency of all inhibitors (the best compound was 45, Ki* = 6 nM). The combination of tert-leucine at P3 and dimethyl substituents at the linker in compound 47 realized a selectivity of 307 against human neutrophil elastase. Compound 45 had an IC50 of 130 nM in a cellular replicon assay, while IC50 for 24 was 400 nM. Several compounds had excellent subcutaneous AUC and bioavailability in rats. Although tripeptide compound 40 was 97% orally bioavailable, larger pentapeptides generally had low oral bioavailability. The X-ray crystal structure of compounds 24 and 45 bound to the protease demonstrated the close interaction of the macrocycle with the Ala156 methyl group and S4 pocket. The strategy of macrocyclization has been proved to be successful in improving potency (> 20-fold greater than that of 1) and in structural depeptization.
• Discovery of (1<i>R</i>,5<i>S</i>)-<i>N</i>-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(<i>S</i>)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(<i>S</i>)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor:  A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection
  作者：Srikanth Venkatraman、Stéphane L. Bogen、Ashok Arasappan、Frank Bennett、Kevin Chen、Edwin Jao、Yi-Tsung Liu、Raymond Lovey、Siska Hendrata、Yuhua Huang、Weidong Pan、Tejal Parekh、Patrick Pinto、Veljko Popov、Russel Pike、Sumei Ruan、Bama Santhanam、Bancha Vibulbhan、Wanli Wu、Weiying Yang、Jianshe Kong、Xiang Liang、Jesse Wong、Rong Liu、Nancy Butkiewicz、Robert Chase、Andrea Hart、Sony Agrawal、Paul Ingravallo、John Pichardo、Rong Kong、Bahige Baroudy、Bruce Malcolm、Zhuyan Guo、Andrew Prongay、Vincent Madison、Lisa Broske、Xiaoming Cui、Kuo-Chi Cheng、Yunsheng Hsieh、Jean-Marc Brisson、Danial Prelusky、Walter Korfmacher、Ronald White、Susan Bogdanowich-Knipp、Anastasia Pavlovsky、Prudence Bradley、Anil K. Saksena、Ashit Ganguly、John Piwinski、Viyyoor Girijavallabhan、F. George Njoroge

  DOI：10.1021/jm060325b

  日期：2006.10.1

  Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-alpha or polyethylene glycol (PEG)-interferon-alpha alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described. X-ray structure of inhibitor 70 complexed with the NS3 protease and biological data are also discussed.
• Potent 7-Hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid-Based Macrocyclic Inhibitors of Hepatitis C Virus NS3 Protease
  作者：Kevin X. Chen、F. George Njoroge、John Pichardo、Andrew Prongay、Nancy Butkiewicz、Nanhua Yao、Vincent Madison、Viyyoor Girijavallabhan

  DOI：10.1021/jm050520a

  日期：2006.1.1

  The NS3 protease of hepatitis C virus (HCV) has emerged as one of the best characterized targets for next-generation HCV therapy. The tetrapeptide 1 and pentapeptide 2 are alpha-ketoamide-type HCV serine protease inhibitors with modest potency. We envisioned that the 1,2,3,4-tetrahydroisoquinoline-3-carboxylamide (Tic) moiety could be cyclized to the P3 capping group. The resulting macrocycle could

  丙型肝炎病毒（HCV）的NS3蛋白酶已成为下一代HCV治疗的最有特色的靶标之一。四肽1和五肽2是具有中等效力的α-酮酰胺型HCV丝氨酸蛋白酶抑制剂。我们设想了1,2,3,4-四氢异喹啉-3-羧酰胺（Tic）部分可以被环化为P3封端基团。所得的大环化合物可通过其与Ala156甲基的额外接触来增强结合。大环化还可以提供肽含量较低的HCV抑制剂。从二肽5开始合成，其是通过两个氨基酸衍生物的偶联而获得的。将N-末端封端为庚-6-烯酰胺，得到6。双键的氢硼化得到醇7，大环8的前体。在Mitsunobu条件下实现了大环化（PPh（3），ADDP）。然后，将大环酸9与适当的右侧片段12、14或16结合，该片段由共同的中间体11制备。最后，α-羟酰胺的氧化提供了目标分子α-酮酰胺17、18和21。然后将末端酯加工成羧酸19和20，以及酰胺20和23。在HCV NS3蛋白酶连续测定中测试了抑制剂17-23。